EU Grants Orphan Drug Designation to Soligenix's Dusquetide for Behçet Disease
SNGX is trading near its 52-week low of $1 (15% above the low) on elevated volume (17× avg).
Summary
Soligenix has received European Union Orphan Drug Designation for its drug candidate, dusquetide (SGX945), for the treatment of Behçet Disease. This designation is a significant positive development, providing up to 10 years of market exclusivity in the EU, along with other incentives like protocol assistance and fee reductions. For a small biopharmaceutical company focused on rare diseases, this regulatory milestone materially enhances the commercial potential and reduces the development risk for dusquetide, building on existing FDA orphan and fast track designations. This news follows supportive Phase 2a data, indicating progress in the drug's clinical development and regulatory pathway.
At the time of this announcement, SNGX was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $1.00 to $6.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: FinanceWire.